Company news

Share this article:
Schering-Plough Corporation announced that it has received antitrust clearance from the Federal Trade Commission regarding its planned acquisition of Organon BioSciences from Akzo Nobel as announced March 12. Organon BioSciences is comprised mainly of Organon, the human pharmaceutical business, and Intervet, the animal health business. It also includes Nobilon, the human vaccine development unit, and Diosynth, the third- party manufacturing unit of Organon. Schering-Plough received approval from The European Commission on Oct. 11, and continues to expect the transaction to be completed by year-end 2007.
Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.